Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Betul Oran

Showing results (21-30 of 141) with videos related to

Pageof 15
Sort By:
Leukemia|January 12, 2026
Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxisRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
Stem Cells Translational Medicine|November 8, 2014
Concise review: umbilical cord blood transplantation: past, present, and futureJavier Munoz, Nina Shah, Katayoun Rezvani, et al.
Blood Advances|June 15, 2025
Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxisYosra M Aljawai, Jeremy Ramdial, Gabriela Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2014
Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?Piyanuch Kongtim, Antonio Di Stasi, Gabriela Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatmentBetul Oran, Michele Donato, Ana Aleman, et al.
JCO Oncology Practice|January 13, 2026
Re-Evaluating Donor Selection Priorities for Hematopoietic Cell Transplantation With Post-Transplant CyclophosphamideRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
American Journal of Hematology|May 12, 2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaBrittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 12, 2018
Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid LeukemiaLauren Veltri, Katayoun Rezvani, Betul Oran, et al.
NPJ Digital Medicine|March 2, 2026
Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomesRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
American Journal of Hematology|February 3, 2023
Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDSCurtis Marcoux, David Marin, Jeremy Ramdial, et al.
Pageof 15

Showing results (21-30 of 141) with videos related to

Sort By:
Pageof 15
Leukemia|January 12, 2026
Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxisRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
Stem Cells Translational Medicine|November 8, 2014
Concise review: umbilical cord blood transplantation: past, present, and futureJavier Munoz, Nina Shah, Katayoun Rezvani, et al.
Blood Advances|June 15, 2025
Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxisYosra M Aljawai, Jeremy Ramdial, Gabriela Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 27, 2014
Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?Piyanuch Kongtim, Antonio Di Stasi, Gabriela Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2007
Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatmentBetul Oran, Michele Donato, Ana Aleman, et al.
JCO Oncology Practice|January 13, 2026
Re-Evaluating Donor Selection Priorities for Hematopoietic Cell Transplantation With Post-Transplant CyclophosphamideRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
American Journal of Hematology|May 12, 2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaBrittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 12, 2018
Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid LeukemiaLauren Veltri, Katayoun Rezvani, Betul Oran, et al.
NPJ Digital Medicine|March 2, 2026
Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomesRohtesh S Mehta, Yosra M Aljawai, Partow Kebriaei, et al.
American Journal of Hematology|February 3, 2023
Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDSCurtis Marcoux, David Marin, Jeremy Ramdial, et al.
Pageof 15